Announcements Trials

Browse Landscape

Phase

Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 18 Gastrointestinal Stromal Tumors 12 Leukemia, Myeloid, Chronic-Phase 9 Leukemia 7 Leukemia, Myeloid, Acute 6 Blast Crisis 6 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Neoplasms 5 Leukemia, Myeloid, Accelerated Phase 5 Gliosarcoma 5 Glioblastoma 5 Brain Neoplasms 5 Glioma 4 Unspecified Adult Solid Tumor, Protocol Specific 3 Prostatic Neoplasms 3 Philadelphia Chromosome 3 Pancreatic Neoplasms 3 Oligodendroglioma 3 Myeloproliferative Disorders 3 Multiple Myeloma 3 Leukemia, Lymphocytic, Chronic, B-Cell 3 Central Nervous System Neoplasms 3 Astrocytoma 3 Primary Myelofibrosis 2 Pdgfra-Associated Chronic Eosinophilic Leukemia 2 Neoplasm Metastasis 2 Myelodysplastic Syndromes 2 Lymphoma, Non-Hodgkin 2 Lung Neoplasms 2 Leukemia, Myelomonocytic, Chronic 2

Interventions

Sirolimus 2 temsirolimus 1 saracatinib 1 Valproic Acid 1 Immunoglobulin G 1 Imatinib Mesylate 1 Hydroxychloroquine 1 Glutamine 1 Disulfides 1 Cetuximab 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Lymphangioleiomyomatosis × Imatinib Mesylate × Clear all

NCT06889168 2026-01-21

LAMP-2

Columbia University

Phase 1 Recruiting

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡